Clinical Trials

The University of North Carolina at Chapel Hill, Department of Neurology, Division of Multiple Sclerosis is continuously recruiting study subjects for on-going clinical trials in the field of Multiple Sclerosis, Neuromyelitis Optica and Neurolyelitis Optica Spectrum Disorder.

We are currently recruiting for the following clinical trials:

  1. A multicenter, randomized, double-blind, placebo- controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD).

    The key entry criteria for this study are:
    • Ages 18 - 74;
    • Have been diagnosed with either NMO or NMOS;
    • Have experienced at least one relapse within last 12 months.

  2. An open-label, multicenter, biomarker study to explore the mechanism of action of Ocrelizumab and b-cell biology in patients with relapsing multiple sclerosis.

    The key entry criteria for this study are:
    • Male or female patients aged 18 – 55 years;
    • EDSS score of 0 − 5.5 points at screening (for patients with EDSS > 5.0 at screening – disease duration has to be less than 15 years;
    • Either treatment-naïve or receiving treatment with disease-modifying therapies (including prior use of IFN-β-1a, IFN-β-1b, or glatiramer acetate;
    • At least one clinically documented relapse in the past year and/or at least one T1-weighted Gd-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment.

  3. A 12-month, randomized, rater-and dose-blinded study to compare the efficacy and safety of fingolimod 0.25mg and 0.5mg administered orally once daily with glatiramer acetate 20mg administered subcutaneously once daily in patients with relapsing- remitting multiple sclerosis.

    The key criteria for this study are:
    • Male and female patients 18 to 65 years of age, inclusive;
    • Patients with RRMS, as defined by 2010 revised McDonald criteria;
    • Patients must be neurologically stable with no onset of relapse within 30 days of randomization;
    • Patients with at least one documented relapse during the previous year or documented relapses during the previous two years before randomization;
    • Patients with an Expanded Disability Status Scale (EDSS) score of 0 to 6.0, inclusive, at screening. A score of 6.0 indicates unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting.

If you or anyone you know matches the above inclusion criteria and is willing to volunteer and enroll in a clinical trial, please contact Faiza Anwar, Clinical Trials Coordinator, at (919) 966-8172, Fax 919-966-2922.